Company
Every investor coverage indicates participated in a round International Vaccine Institute raised.
Companies International Vaccine Institute acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming International Vaccine Institute. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brisbane vaccine patch maker Vaxxas won a $5.4 million Wellcome grant for studies and a Phase I trial of a typhoid vaccine using its HD-MAP technology, developed with SK bioscience.